Clinical trial · Interventional
Open Label Trial to Assess Iressa in Prostate Cancer Patients
Phase II, Open-Label Trial to Assess the Activity of ZD1839 (IRESSA TM) in Patients With Recurrent Prostate Cancer Who Have Rising Serum PSA Levels Despite Serum Testosterone < 50mg/dl
NCT00635856CI-TRIAL-00002247completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gefitinib | Drug | Gefitinib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Serum Prostate Specific Antigen
- timeFrame
- Monthly
Secondary outcomes (3)
- measure
- Duration of PSA decline
- timeFrame
- Monthly
- measure
- Safety variables
- timeFrame
- Monthly
- measure
- Time to Progression
- timeFrame
- Every 3 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Prostate cancer diagnosis * no evidence of metastasis * Age 18 or older Exclusion Criteria: * Prior chemotherapy for recurrent prostate cancer * Radiotherapy completed within 28 days of starting the study * Incomplete healing from prior cancer or other major surgery
References
Publications (0)
Data not yet available
No reference posted for this study.